Trial in progress: A phase 1b/2 study of GB5121, a brain-penetrant, potent, highly selective, and irreversible BTK inhibitor for relapsed/refractory primary/secondary CNS lymphoma and primary vitreoretinal lymphoma Meeting Abstract
| Authors: | Soussain, C.; Issa, S.; Lewis, K. L.; Grommes, C.; Fox, J.; Ward, R.; Peterson, C.; Cravets, M.; Mathias, A.; Sosa, J.; Kirby, B. J.; Ding, Z.; Yusuf, I.; Rose, M. J.; Steinberg, M. W.; Tun, H. W. |
| Abstract Title: | Trial in progress: A phase 1b/2 study of GB5121, a brain-penetrant, potent, highly selective, and irreversible BTK inhibitor for relapsed/refractory primary/secondary CNS lymphoma and primary vitreoretinal lymphoma |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 12068 |
| End Page: | 12069 |
| Language: | English |
| ACCESSION: | WOS:000893230305045 |
| DOI: | 10.1182/blood-2022-158599 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
